News | October 23, 2013

St. Luke’s Medical Center Offers Molecular Breast Imaging

Technology provides accurate identification of tumors in women with dense breasts, implants

mammography systems nuclear imaging st. luke's discovery nm 750b GE healthcare
October 23, 2013 — St. Luke’s Medical Center is the first hospital in the Texas Medical Center to offer a molecular breast imaging (MBI) device that is sensitive enough to detect tiny tumors.  GE Healthcare’s Discovery NM 750b is designed to help improve detection of breast cancer, even in women with dense breasts where results of mammography may be inconclusive.
“The Discovery system is an important advancement in the early detection and diagnosis of breast cancer, but for women with dense breasts, it could truly be a lifesaver,” said Eric Ladwig, operations manager, nuclear medicine, St. Luke’s Medical Center. “Women with dense breasts have an increased risk of breast cancer and this condition can impact the quality of a traditional mammogram. MBI is not affected by breast density, resulting in a clear image and great confidence that the patient is cancer free or truly needs to have a biopsy.”
MBI is a comfortable examination, as only light immobilization pressure is required during studies versus a traditional mammography.
During an MBI procedure with Discovery, a patient receives a tracer injection that locates metabolically active tumors by blood flow. Because the tumor metabolizes the isotope to a higher degree than normal tissue, it will appear as a “hot spot” on the scan.
For more information:

Related Content

News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC Debuts  Spanish Language Video  About Dense Breasts
News | Breast Density | September 12, 2017
Breast cancer risks associated with breast density are the subject of a new Spanish language video launched recently by...
Asian Study Underlines Potential Value of Pressure-Guided Mammography
News | Mammography | September 11, 2017
Sigmascreening recently announced that a study of in total 15,898 in digital mammograms from 3,772 Asian women...
Delphinus Enrolls First Patient in Discover Breast Ultrasound Clinical Project
News | Ultrasound Womens Healthcare | September 08, 2017
September 8, 2017 — Delphinus Medical Technologies Inc.
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Overlay Init